Nyxoah SA (NYXH)
NASDAQ: NYXH · Real-Time Price · USD
6.70
-0.32 (-4.56%)
At close: Aug 12, 2025, 4:00 PM
6.69
-0.01 (-0.15%)
After-hours: Aug 12, 2025, 4:00 PM EDT
Company Description
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA).
The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.
Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Nyxoah SA
| Country | Belgium |
| Founded | 2009 |
| IPO Date | Jul 2, 2021 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 184 |
| CEO | Olivier Taelman |
Contact Details
Address: Rue Edouard Belin 12 Mont-Saint-Guibert, 1435 Belgium | |
| Phone | 32 1 022 23 55 |
| Website | nyxoah.com |
Stock Details
| Ticker Symbol | NYXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $30.00 |
| CIK Code | 0001857190 |
| ISIN Number | BE0974358906 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Olivier Taelman | Chief Executive Officer and Executive Director |
| Robert Taub MBA | Co-Founder and Chairman |
| John Landry | Chief Financial Officer |
| Bruno Onkelinx | Chief Technical Officer |
| Mikaela Kirkwood | Corporate Communication and Investor Relations Manager |
| An Moonen | General Counsel |
| Maggie McGowan | Chief Human Resources Officer |
| Loic Moreau | President of International |
| Remi Renard | Chief of Staff |
| Jeyakumar Subbaroyan | Chief Clinical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 11, 2025 | 6-K | Report of foreign issuer |
| Jul 29, 2025 | 6-K | Report of foreign issuer |
| Jun 27, 2025 | 6-K | Report of foreign issuer |
| Jun 16, 2025 | 6-K | Report of foreign issuer |
| May 30, 2025 | 6-K | Report of foreign issuer |
| May 27, 2025 | 6-K | Report of foreign issuer |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 14, 2025 | 6-K | Report of foreign issuer |
| May 9, 2025 | 6-K | Report of foreign issuer |
| May 9, 2025 | 6-K | Report of foreign issuer |